ftc pharmacy benefit managers

Pharmacy benefit managers inflated drug prices by $7.3B

Pharmacy Benefit Managers Not Thrilled With FTC Report Finding Pharmacy Benefit Managers Raise Drug Prices

The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report examines the impact of PBMs (specifically CVS Caremark,

Honolulu Star-Advertiser · 2d

FTC: Pharmacy benefit managers inflated drug prices by $7.3B

WASHINGTON >> The nation’s three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including for heart disease, cancer and HIV, at their affiliated pharmacies,

Reuters · 3d

US FTC finds major pharmacy benefit managers inflated drug prices for $7.3 billion gain

The nation's three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including for heart disease, cancer and HIV, at their affiliated pharmacies, the U.S.

3don MSN

PBMs made billions marking up specialty drugs by more than 1,000 percent: FTC

The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...

1don MSN

UnitedHealth Charged Cancer Patients 5000%, Bombshell FTC Report Claims

The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's Express Scripts—marked up prices at their pharmacies by hundreds or thousands ...

policymed.com2d

Second Federal Trade Commission Report on Pharmacy Benefit Managers (PBM’s) Focuses on Specialty Generics

The Federal Trade Commission (FTC) released its second interim staff report “Specialty Generic Drugs a Growing Profit Center ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Pharmacy benefit managers inflated drug prices by $7.3B

Trending now